An Open-Label, Multicenter, Phase I Trial Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma
Latest Information Update: 17 Jul 2024
At a glance
- Drugs RO 7297089 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; First in man
- Sponsors Genentech
Most Recent Events
- 01 Jun 2022 Status changed from active, no longer recruiting to completed.
- 04 Feb 2022 Planned End Date changed from 31 May 2023 to 14 Feb 2022.
- 14 Dec 2021 Results (n=21; Data cut off date- 30 Apr 2021) presented at the 63rd American Society of Hematology Annual Meeting and Exposition